New research from Mount Sinai School of Medicine has found that the price in New York and New Jersey of the medications most commonly prescribed for patients with diabetes varies widely depending on where you shop.
Read More »Diabetes In Control
June 3, 2009, Issue #471
A couple of weeks ago we had a new product blurb about Cycloset™, an old drug with a new indication for diabetes. Many of you wrote to ask me for information on how the medication works and where the idea came from. I had our current PharmD candidate, Robert Fredenrich, …
Read More »ADA – Exenatide Not Associated with Increased Rate of Acute Pancreatitis Compared to other Antidiabetic Drugs
Retrospective Cohort Study included more than 25,000 BYETTA patients accrued over three years … Full Story
Read More »Snoring Pregnant Women at Higher Risk for Gestational Diabetes
If you are pregnant and your mate complains your frequent snoring is rattling the bedroom windows, you may have bigger problems than an annoyed, sleep-deprived partner
Read More »ADA – Inhaled Insulin AFRESA(R) Controls Post-Meal Sugar Levels with Less Weight Gain and Hypoglycemia
The findings of two 52-week studies show that the investigational ultra rapid acting insulin AFRESA® (insulin human [rDNA origin]) Inhalation Powder combined with basal insulin is comparable to standard of care therapies in controlling post-meal blood sugar levels, and also results in significantly less weight gain and risk of hypoglycemia …
Read More »ADA – Diabetes Associated with Hearing Loss
Diabetic patients with poor glycemic control or vascular or neuropathic complications may also suffer from hearing loss. All patients with hemoglobin A1c levels greater than 7% had hearing impairment.
Read More »ADA – Once-Weekly Exenatide Provides Glycemic Control and Weight Loss
Once-weekly exenatide (EQW) produces superior improvements in glucose control and body weight compared with maximum daily doses of sitagliptin and pioglitazone on background metformin, according to study results presented at the American Diabetes Association (ADA) 69th Scientific Sessions.
Read More »ADA – Saxagliptin Lowers Glucose, Reduces Cardiovascular Events
Saxagliptin, an investigational dipeptidyl peptidase-4 (DPP4) inhibitor, may offer cardioprevention as a side benefit of diabetes treatment, according to a meta-analysis.
Read More »ADA – Liraglutide Reverses Prediabetes 90%
Researchers at the ADA reported that Liraglutide reverses prediabetes indices in most obese patients with existing prediabetes …Full Story
Read More »ADA – New Dual PPAR Agonist Promising for Diabetes
Aleglitazar, a novel dual peroxisome proliferator-activated receptor (PPAR) agonist, is effective for glucose control in Type 2 diabetes and reduces A1c 1.3%.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.